SETD2 and systemic mastocytosis: Martinelli et al. reported loss of function mutations of SETD2 in a series of 53 SM patients and have suggested that reduced SETD2 expression/absence and H3K36Me3 deficiency might potentiate the effects of KIT constitutive activation to determine the phenotype of advanced SM [54].